CAS Medical Systems, Inc. (CASM) EPS Estimated At $-0.07

July 14, 2018 - By Elena Maslow

CAS Medical Systems, Inc. (NASDAQ:CASM) LogoInvestors sentiment increased to 1.4 in 2018 Q1. Its up 0.40, from 1 in 2017Q4. It improved, as 2 investors sold CAS Medical Systems, Inc. shares while 3 reduced holdings. 2 funds opened positions while 5 raised stakes. 6.50 million shares or 1.24% more from 6.42 million shares in 2017Q4 were reported.
California Public Employees Retirement Sys holds 0% in CAS Medical Systems, Inc. (NASDAQ:CASM) or 10,400 shares. 22,400 were reported by Penbrook Mgmt Ltd Liability. Ontario – Canada-based Royal Savings Bank Of Canada has invested 0% in CAS Medical Systems, Inc. (NASDAQ:CASM). Wells Fargo And Mn owns 227 shares. Bancshares Of America De owns 541 shares for 0% of their portfolio. Horizon Kinetics Llc reported 99,546 shares. Acuta Capital Prtnrs Limited Liability has invested 1.07% in CAS Medical Systems, Inc. (NASDAQ:CASM). Guggenheim Capital holds 0% in CAS Medical Systems, Inc. (NASDAQ:CASM) or 12,246 shares. Hightower Advsrs Lc holds 0% or 240,889 shares. Moreover, Rmb Cap Mgmt Ltd Liability Com has 0% invested in CAS Medical Systems, Inc. (NASDAQ:CASM). 532,365 were accumulated by Vanguard Group Inc Inc. Blackrock holds 12,566 shares or 0% of its portfolio. Morgan Stanley stated it has 2,378 shares. Renaissance Technologies Limited Liability has invested 0% of its portfolio in CAS Medical Systems, Inc. (NASDAQ:CASM). Northern Corporation accumulated 25,101 shares.

Since March 15, 2018, it had 0 buys, and 4 insider sales for $44,489 activity.

Analysts expect CAS Medical Systems, Inc. (NASDAQ:CASM) to report $-0.07 EPS on August, 14.They anticipate $0.02 EPS change or 22.22 % from last quarter’s $-0.09 EPS. After having $-0.07 EPS previously, CAS Medical Systems, Inc.’s analysts see 0.00 % EPS growth. The stock increased 3.13% or $0.06 during the last trading session, reaching $1.98. About 237,436 shares traded or 49.91% up from the average. CAS Medical Systems, Inc. (NASDAQ:CASM) has risen 67.37% since July 14, 2017 and is uptrending. It has outperformed by 54.80% the S&P500.

CAS Medical Systems, Inc., a non-invasive cerebral oximetry technology company, develops, makes, and markets non-invasive patient monitoring products worldwide. The company has market cap of $54.76 million. The Company's FORE-SIGHT® Absolute Cerebral Oximeter provides non-invasive and continuous measurement of absolute cerebral tissue oxygenation in the brain for patients during critical care. It currently has negative earnings. The firm provides FORE-SIGHT tissue oximeter monitors, sensors, and accessories.

More news for CAS Medical Systems, Inc. (NASDAQ:CASM) were recently published by: Investingnews.com, which released: “Medical Device Update: Q2 2018 in Review” on July 12, 2018. Benzinga.com‘s article titled: “Benzinga’s Daily Biotech Pulse: Sarepta’s DMD Gene Therapy, Anika’s Flunked Trial, Eidos To Commence Trading” and published on June 20, 2018 is yet another important article.

CAS Medical Systems, Inc. (NASDAQ:CASM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.